Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

Description

Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet. Not getting enough sleep can lead to health problems like heart attacks, diabetes, and even cancer. Since individuals with psoriasis have these same health problems, getting better sleep may help to keep them happier and healthier. This study will look at how individuals with psoriasis sleep and if their sleep is different than indivuduals without psoriasis.

Conditions

Psoriasis Vulgaris

Talk to us

Study Overview

On this page

Study Details

Study overview

Getting enough sleep is important for maximizing health and well-being. When it comes to health, sleep is as vital as regular exercise and eating a balanced diet. Not getting enough sleep can lead to health problems like heart attacks, diabetes, and even cancer. Since individuals with psoriasis have these same health problems, getting better sleep may help to keep them happier and healthier. This study will look at how individuals with psoriasis sleep and if their sleep is different than indivuduals without psoriasis.

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

Dermatologic Research Evaluation and Monitoring of Sleep in Moderate-to-Severe Psoriasis

Condition
Psoriasis Vulgaris
Intervention / Treatment

-

Contacts and Locations

San Francisco

UCSF Psorisis Center, San Francisco, California, United States, 94118

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients with a diagnosis of moderate to severe plaque type psoriasis confirmed by the principal investigator. Moderate to severe psoriasis will be defined as affected BSA ≥3%. Healthy controls will be age and sex matched (see below) subjects with no prior or current history of psoriasis.
  • 2. Are at least 18 years of age
  • 3. Psoriasis has been stable over the last 3 months
  • 4. Psoriasis is either untreated or treated only with topicals at the current time (see exclusion criteria for washout times)
  • 5. Subjectively reported poor sleep quality using the Pittsburg Sleep Quality Index (PSQI) (defined as a global score \>5)
  • 6. Fluent in English
  • 7. Demonstrate understanding of the study and willingness to participate as evidenced by voluntary informed consent
  • 1. Patients with guttate, erythrodermic, or pustular psoriasis subtypes
  • 2. Having a previous diagnosis of obstructive sleep apnea (OSA) or another medically defined sleep disorder or fall into the intermediate or high-risk groups for having OSA as calculated by the STOP-BANG questionnaire
  • 3. Subjects who have used the following treatments for psoriasis: phototherapy (UVB) in the last 2 weeks, photochemotherapy (PUVA) in the last 4 weeks, oral systemic treatments in the last 4 weeks, biologic immunomodulating agents in the last 12 weeks, or have had exposure to any other investigational drug/device within 30 days prior to study entry
  • 4. Subjects who have used any over the counter or prescription sleep aids within five half-lives of the agent in question.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of California, San Francisco,

Tina Bhutani, MD, MAS, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

2024-05-31